The changing trends in MDR TB management

Abstract

The last decade was about WHO developing and issuing evidence-based policy recommendations on managing and caring for patients with drug-resistant tuberculosis. Several new medications and regimens have lately been brought together to control the DR-TB epidemic, along with various diagnostic tools and preventative strategies. The earlier long term regimen (LTR) of a 2-year standardized regimen including second-line injectables (SLI) is now replaced by a shorter treatment regimen (STR) for Fluoroquinolone (FQ) sensitive patients and LTR-1, LTR-2 and LTR-3, depending on past drug history and results of drug susceptibility testing.